ALBO Stock Overview
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
Albireo Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$19.57|
|52 Week High||US$37.63|
|52 Week Low||US$16.02|
|1 Month Change||10.69%|
|3 Month Change||-1.46%|
|1 Year Change||-35.13%|
|3 Year Change||3.44%|
|5 Year Change||-9.23%|
|Change since IPO||34.04%|
Recent News & Updates
Albireo gains on royalty agreement for pruritus therapy
Albireo Pharma, Inc. (NASDAQ:ALBO) added ~7% in the morning hours Thursday after the biotech focused on liver diseases announced an agreement with asset manager Sagard Healthcare Partners to sell royalties from the company's FDA-approved pruritus therapy Bylvay. Per the terms, Sagard will provide ALBO with a $115M upfront payment in return for a mid-single digit average royalty rate on Bylvay's global annual net revenues. The total royalties are capped at 1.6x of invested capital if repaid before Dec. 31, 2028, and 2.0x if repaid after that. The agreement ends with the achievement of the capped amount. The deal allows the company to extend its cash runway beyond at least 2024 when topline data is expected from the BOLD Phase 3 study for Bylvay in patients with biliary atresia. "These additional resources allow us to build Bylvay into a billion-dollar product and advance the development of our early asset pipeline," ALBO Chief Executive Ron Cooper remarked.
Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Albireo Pharma (NASDAQ:ALBO) said the Italian Medicines Agency has enabled reimbursed access to Bylvay (odevixibat) to treat all types of patients with progressive familial intrahepatic cholestasis (PFIC) in Italy. PFIC is a rare progressive, liver disease. Bylvay was granted Full Therapeutic Innovation status by Agenzia Italiana del Farmaco (AIFA), a designation for some products with unmet need and added clinical benefit, Albireo said in a Sept. 6 press release.
These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Market forces rained on the parade of Albireo Pharma, Inc. ( NASDAQ:ALBO ) shareholders today, when the analysts...
|ALBO||US Biotechs||US Market|
Return vs Industry: ALBO underperformed the US Biotechs industry which returned -27.4% over the past year.
Return vs Market: ALBO underperformed the US Market which returned -22.1% over the past year.
|ALBO Average Weekly Movement||13.2%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ALBO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: ALBO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases.
Albireo Pharma Fundamentals Summary
|ALBO fundamental statistics|
Is ALBO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALBO income statement (TTM)|
|Cost of Revenue||US$2.37m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.85|
|Net Profit Margin||-70.79%|
How did ALBO perform over the long term?See historical performance and comparison
Is ALBO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALBO?
Other financial metrics that can be useful for relative valuation.
|What is ALBO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ALBO's PS Ratio compare to its peers?
|ALBO PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
PTGX Protagonist Therapeutics
KPTI Karyopharm Therapeutics
IDYA IDEAYA Biosciences
SLNC.F Silence Therapeutics
ALBO Albireo Pharma
Price-To-Sales vs Peers: ALBO is good value based on its Price-To-Sales Ratio (7.5x) compared to the peer average (12.6x).
Price to Earnings Ratio vs Industry
How does ALBO's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: ALBO is good value based on its Price-To-Sales Ratio (7.5x) compared to the US Biotechs industry average (12.7x)
Price to Sales Ratio vs Fair Ratio
What is ALBO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||7.5x|
|Fair PS Ratio||22.5x|
Price-To-Sales vs Fair Ratio: ALBO is good value based on its Price-To-Sales Ratio (7.5x) compared to the estimated Fair Price-To-Sales Ratio (22.5x).
Share Price vs Fair Value
What is the Fair Price of ALBO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ALBO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALBO's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Albireo Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALBO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALBO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALBO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALBO's revenue (58% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: ALBO's revenue (58% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALBO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Albireo Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALBO is currently unprofitable.
Growing Profit Margin: ALBO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALBO is unprofitable, and losses have increased over the past 5 years at a rate of 16.1% per year.
Accelerating Growth: Unable to compare ALBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: ALBO has a negative Return on Equity (-31.9%), as it is currently unprofitable.
Discover strong past performing companies
How is Albireo Pharma's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALBO's short term assets ($195.8M) exceed its short term liabilities ($43.6M).
Long Term Liabilities: ALBO's short term assets ($195.8M) exceed its long term liabilities ($71.7M).
Debt to Equity History and Analysis
Debt Level: ALBO has more cash than its total debt.
Reducing Debt: ALBO's debt to equity ratio has increased from 2.6% to 8.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALBO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALBO has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 38.9% each year.
Discover healthy companies
What is Albireo Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Albireo Pharma Dividend Yield vs Market|
|Company (Albireo Pharma)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Biotechs)||2.7%|
|Analyst forecast in 3 Years (Albireo Pharma)||n/a|
Notable Dividend: Unable to evaluate ALBO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALBO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALBO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALBO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALBO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ron Cooper (59 yo)
Mr. Ronald H. W. Cooper, also known as Ron, serves as Independent Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 20...
CEO Compensation Analysis
|Ron Cooper's Compensation vs Albireo Pharma Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$6m||US$590k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$3m||US$570k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$3m||US$551k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$4m||US$530k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$2m||US$460k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$4m||US$400k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$352k||US$221k|
Compensation vs Market: Ron's total compensation ($USD6.04M) is above average for companies of similar size in the US market ($USD2.92M).
Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.
Experienced Management: ALBO's management team is considered experienced (4 years average tenure).
Experienced Board: ALBO's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Albireo Pharma, Inc.'s employee growth, exchange listings and data sources
- Name: Albireo Pharma, Inc.
- Ticker: ALBO
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$383.817m
- Shares outstanding: 19.61m
- Website: https://www.albireopharma.com
Number of Employees
- Albireo Pharma, Inc.
- 10 Post Office Square
- Suite 1000
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BDQM||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2016|
|ALBO||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Nov 2016|
|ALBO *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Nov 2016|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.